Literature DB >> 10377322

Cardiac involvement in Emery Dreifuss muscular dystrophy: a case series.

A E Buckley1, J Dean, I R Mahy.   

Abstract

Three patients with Emery Dreifuss muscular dystrophy are reported. Emery Dreifuss muscular dystrophy is an X linked muscular dystrophy, in which locomotor involvement is characteristically mild and slowly progressive. The effect on the heart becomes apparent in the teenage years and is characterised by cardiac conduction defects and infiltration of the myocardium by fibrous and adipose tissue. It first affects the atria, which results in atrial paralysis; treatment with ventricular pacing is usually needed. Female carriers can develop heart problems and are at risk of sudden death. Relatives of affected patients should be offered screening with electrocardiography and echocardiography.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10377322      PMCID: PMC1729116          DOI: 10.1136/hrt.82.1.105

Source DB:  PubMed          Journal:  Heart        ISSN: 1355-6037            Impact factor:   5.994


  10 in total

1.  Emery-Dreifuss muscular dystrophy in the evaluation of decreased spinal mobility and joint contractures.

Authors:  Kamil Goncu; Rengin Guzel; Fusun Guler-Uysal
Journal:  Clin Rheumatol       Date:  2003-10-21       Impact factor: 2.980

Review 2.  Dilated cardiomyopathy.

Authors:  Neal K Lakdawala; Jeffery R Winterfield; Birgit H Funke
Journal:  Circ Arrhythm Electrophysiol       Date:  2012-09-28

3.  A novel de novo mutation in Lamin A/C gene in Emery Dreifuss Muscular Dystrophy patient with atrial paralysis.

Authors:  Chaerul Achmad; Almira Zada; Mardlatillah Affani; Mohammad Iqbal; Erwan Martanto; Augustine Purnomowati; Toni M Aprami
Journal:  J Atr Fibrillation       Date:  2017-04-30

Review 4.  [Cardiac manifestations of muscular dystrophies].

Authors:  A Perrot; S Spuler; C Geier; R Dietz; K J Osterziel
Journal:  Z Kardiol       Date:  2005-05

Review 5.  Atrial cardiopathy: a broadened concept of left atrial thromboembolism beyond atrial fibrillation.

Authors:  Hooman Kamel; Peter M Okin; W T Longstreth; Mitchell S V Elkind; Elsayed Z Soliman
Journal:  Future Cardiol       Date:  2015-05

Review 6.  Cardiac involvement in patients with muscular dystrophies: magnetic resonance imaging phenotype and genotypic considerations.

Authors:  David Verhaert; Kathryn Richards; Jill A Rafael-Fortney; Subha V Raman
Journal:  Circ Cardiovasc Imaging       Date:  2011-01       Impact factor: 7.792

7.  Immunohistochemistry on a panel of Emery-Dreifuss muscular dystrophy samples reveals nuclear envelope proteins as inconsistent markers for pathology.

Authors:  Phu Le Thanh; Peter Meinke; Nadia Korfali; Vlastimil Srsen; Michael I Robson; Manfred Wehnert; Benedikt Schoser; Caroline A Sewry; Eric C Schirmer
Journal:  Neuromuscul Disord       Date:  2016-12-21       Impact factor: 4.296

8.  X-Linked Emery-Dreifuss Muscular Dystrophy: Study Of X-Chromosome Inactivation and Its Relation with Clinical Phenotypes in Female Carriers.

Authors:  Emanuela Viggiano; Agnieszka Madej-Pilarczyk; Nicola Carboni; Esther Picillo; Manuela Ergoli; Stefania Del Gaudio; Michal Marchel; Gerardo Nigro; Alberto Palladino; Luisa Politano
Journal:  Genes (Basel)       Date:  2019-11-11       Impact factor: 4.096

9.  Echocardiographic Features of Cardiomyopathy in Emery-Dreifuss Muscular Dystrophy.

Authors:  Michał Marchel; Agnieszka Madej-Pilarczyk; Agata Tymińska; Roman Steckiewicz; Janusz Kochanowski; Julia Wysińska; Ewa Ostrowska; Paweł Balsam; Marcin Grabowski; Grzegorz Opolski
Journal:  Cardiol Res Pract       Date:  2021-02-04       Impact factor: 1.866

10.  Deep clinicopathological phenotyping identifies a previously unrecognized pathogenic EMD splice variant.

Authors:  Daniel G Calame; Jawid M Fatih; Isabella Herman; Zeynep Coban-Akdemir; Haowei Du; Tadahiro Mitani; Shalini N Jhangiani; Dana Marafi; Richard A Gibbs; Jennifer E Posey; Vidya P Mehta; Carrie A Mohila; Farida Abid; Timothy E Lotze; Davut Pehlivan; Adekunle M Adesina; James R Lupski
Journal:  Ann Clin Transl Neurol       Date:  2021-09-15       Impact factor: 4.511

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.